ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2026
Antidepressant medications have differential effects on REM sleep without atonia quantified by chin and upper extremity EMG.
Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expanding the interpretation of REM sleep without atonia in antidepressant users.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine associations between video polysomnography (vPSG)-quantified REM sleep without atonia (RSWA) and antidepressants (ADs) including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs).
methodsWe analyzed 1474 vPSGs scored for possible REM sleep behavior disorder (RBD). RSWA scoring was based on submentalis and flexor digitorum superficialis (FDS) EMG using AASM criteria. Percent REM epochs meeting RSWA criteria (RSWA%) were compared by medication class in monotherapy or combination therapies using linear regression analysis, and adjusting for age, body mass index, gender, and race.
resultsThe sample included 1474 patients, 624 (42.3%) taking ADs and 850 (57.7%) non-users. Mean age was 53 ± 16.4 years, 53.1% male, and 73.1% White. Overall RSWA% was 11.9 ± 17.8. Compared to those medication-free, patients on SSRI or SNRI monotherapy had a 3.39% and 6.66% increase in RSWA%, respectively (p < 0.009 and p < 0.001); those on both SSRI and SNRI had a 10.44% increase (p = 0.089). In contrast, RSWA% did not increase in patients taking TCA monotherapy or the combination of SSRI + TCA or SNRI + TCA.
conclusionUse of SSRIs and SNRIs, but not TCAs, is associated with increased RSWA% in a population with suspected parasomnia. The highest RSWA% estimates among combination groups were observed with SSRI + SNRI, although combination subgroup findings should be interpreted cautiously given small sample sizes. This study is the largest to quantify RSWA% and identify the differential impact of AD class, and monotherapy versus combination therapy on RSWA%. These findings should be interpreted within the context of the clinical criteria used for RSWA scoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.